Cargando…

Evaluation of the EPR Effect in the CAM-Model by Molecular Imaging with MRI and PET Using (89)Zr-Labeled HSA

SIMPLE SUMMARY: The CAM model is a promising alternative to murine models in terms of the 3Rs principles. However, its value for the noninvasive assessment of the biodistribution and accumulation of radiolabeled macromolecules by PET and MR imaging needs further evaluation. Thus, we analyzed the bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hilbrig, Colmar, Löffler, Jessica, Fischer, Gabriel, Scheidhauer, Ellen, Solbach, Christoph, Huber-Lang, Markus, Beer, Ambros J., Rasche, Volker, Winter, Gordon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954539/ https://www.ncbi.nlm.nih.gov/pubmed/36831469 http://dx.doi.org/10.3390/cancers15041126

Ejemplares similares

Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging
por: Löffler, Jessica, et al.
Publicado: (2022)

Comparison of Quantification of Target-Specific Accumulation of [(18)F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI
por: Löffler, Jessica, et al.
Publicado: (2021)

Preclinical PET and MR Evaluation of (89)Zr- and (68)Ga-Labeled Nanodiamonds in Mice over Different Time Scales
por: Winter, Gordon, et al.
Publicado: (2022)

Multi-Modal PET and MR Imaging in the Hen’s Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands
por: Winter, Gordon, et al.
Publicado: (2020)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

Diagnostic significance of MRI versus CT using identical PET data in patients with recurrent differentiated thyroid cancer: A PET/MRI study
por: Westphal, Korbinian, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Novel (89)Zr cell labeling approach for PET-based cell trafficking studies
por: Bansal, Aditya, et al.
Publicado: (2015)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

(89)Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging
por: Kuda-Wedagedara, Akhila N. W., et al.
Publicado: (2017)

Feasibility of PET/CT system performance harmonisation for quantitative multicentre (89)Zr studies
por: Kaalep, Andres, et al.
Publicado: (2018)

PET Imaging of Acidic Tumor Environment With (89)Zr-labeled pHLIP Probes
por: Bauer, David, et al.
Publicado: (2022)

(89)Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model
por: Stone, Logan D., et al.
Publicado: (2022)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
por: Gawne, Peter J., et al.
Publicado: (2020)

PET/CT Imaging of (89)Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys
por: Li, Wenping, et al.
Publicado: (2020)

A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for (89)Zr PET Imaging
por: Russelli, Lisa, et al.
Publicado: (2021)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

In Vivo PET Imaging of Monocytes Labeled with [(89)Zr]Zr-PLGA-NH(2) Nanoparticles in Tumor and Staphylococcus aureus Infection Models
por: Krekorian, Massis, et al.
Publicado: (2021)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
por: Ikotun, Oluwatayo F., et al.
Publicado: (2013)

Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B
por: Ma, Michelle T., et al.
Publicado: (2015)

Pet imaging of cytotoxic human T cells using an 89Zr-labeled anti-CD8 minibody
por: Olafsen, Tove, et al.
Publicado: (2015)

Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis
por: Park, Bok-Nam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dfougq51fchu4nu8ojhqid5ku5